| Press Release | ||
 | ||
 | ||
|
Indevus Announces FDA Approval of Sanctura® XR Indevus Pharmaceuticals, Inc (Nasdaq: IDEV), a Supernus Pharmaceuticals Partner, today announced that Sanctura® XR (trospium chloride extended release capsules) has been approved by the U.S. Food and Drug Administration (FDA). For further information on Indevus and to view the content of the official Press Release, please click on the following link: |
|
